Search results
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
Char-Koosta News· 3 days agoSAN FRANCISCO and SUZHOU, China, April 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc....
Mercy BioAnalytics to Present Results from a Large Ovarian Cancer Screening Study at the ASCO Annual...
Denton Record-Chronicle· 3 days agoMercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, will present data at the 2024 American Society of Clinical Oncology (
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoCarisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire PHILADELPHIA, April 24, 2024 PHILADELPHIA ...
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual...
Benzinga· 3 days agoREDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8
...Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20...
Brenham Banner-Press· 3 days agoDizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological diseases, announced today that two abstracts ...
BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024
Digital Journal· 3 days ago"We are very pleased to be chosen to present data from our two lead candidates, BI-1808 (anti-TNFR2) and BI-1206 (anti-FccgRIIB) at ASCO 2024. Our research suggests that each ...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
FOX 59 Indianapolis· 3 days agoFirst-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced...
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of...
Morningstar· 2 days agoROCKVILLE, Md., April 25, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development ...
...Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20...
The Longview News-Journal· 3 days ago...a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological diseases, announced today that two abstracts featuring the latest data on sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)...
...COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal...
Morningstar· 2 days agoHOLON, Israel, April 25, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 (